Zur Rose Group: gematik awards tender for specialist e-prescription service - Zur Rose subsidiary eHealth-Tec involved as partner to IBM
|
Zur Rose Group AG / Key word(s): Tender Offer Ad hoc announcement gematik awards tender for specialist e-prescription service - Zur Rose subsidiary eHealth-Tec involved as partner to IBM eHealth-Tec works as a technology provider in strategic partnerships with health insurers and others in the healthcare industry to successfully implement pilot e-prescription projects that are relevant to the market. eHealth-Tec contributed its accumulated experience as a systems provider for e-prescription solutions in the IBM submission. The successful participation in the gematik tender reinforces the role played by the Zur Rose Group as a pioneer in successfully introducing electronic prescriptions in Germany. Investors and analyst contact Media contacts Segment Germany of the Zur Rose Group: Agenda Zur Rose Group The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. It also operates the leading marketplace in southern Europe for consumer health, beauty and personal care products commonly sold in pharmacies. The company is internationally present with strong brands, including Germany's best-known pharmacy brand DocMorris. Zur Rose employs more than 1,800 people at sites in Switzerland, Germany, the Netherlands, Spain and France. In 2019 it generated revenue of CHF 1,569 million (including medpex) and currently has around ten million active customers in core European markets. With its business model, the Zur Rose Group offers high-quality, safe and cost-effective pharmaceutical care. It is also characterized by the continuous further development of digital services in the field of drug management using AI-supported applications and new technology. Zur Rose is furthermore actively driving ahead its positioning as a comprehensive provider of healthcare services. By creating a digital healthcare platform - the Zur Rose ecosystem - it networks products and digital services from qualified providers. The contribution made by Zur Rose will be to take these offerings to customers and patients and to make a relevant selection. The aim is to provide people with a seamless accompaniment and empower them to manage their own health optimally using products and digital solutions. The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). For further information please see zurrosegroup.com. End of ad hoc announcement Information and Explanation of the Issuer to this News: Ad hoc announcement gematik awards tender for specialist e-prescription service - Zur Rose subsidiary eHealth-Tec involved as partner to IBM eHealth-Tec works as a technology provider in strategic partnerships with health insurers and others in the healthcare industry to successfully implement pilot e-prescription projects that are relevant to the market. eHealth-Tec contributed its accumulated experience as a systems provider for e-prescription solutions in the IBM submission. The successful participation in the gematik tender reinforces the role played by the Zur Rose Group as a pioneer in successfully introducing electronic prescriptions in Germany. Investors and analyst contact Media contacts Segment Germany of the Zur Rose Group: Agenda Zur Rose Group The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. It also operates the leading marketplace in southern Europe for consumer health, beauty and personal care products commonly sold in pharmacies. The company is internationally present with strong brands, including Germany's best-known pharmacy brand DocMorris. Zur Rose employs more than 1,800 people at sites in Switzerland, Germany, the Netherlands, Spain and France. In 2019 it generated revenue of CHF 1,569 million (including medpex) and currently has around ten million active customers in core European markets. With its business model, the Zur Rose Group offers high-quality, safe and cost-effective pharmaceutical care. It is also characterized by the continuous further development of digital services in the field of drug management using AI-supported applications and new technology. Zur Rose is furthermore actively driving ahead its positioning as a comprehensive provider of healthcare services. By creating a digital healthcare platform - the Zur Rose ecosystem - it networks products and digital services from qualified providers. The contribution made by Zur Rose will be to take these offerings to customers and patients and to make a relevant selection. The aim is to provide people with a seamless accompaniment and empower them to manage their own health optimally using products and digital solutions. The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). For further information please see zurrosegroup.com. |
| Language: | English |
| Company: | Zur Rose Group AG |
| Walzmühlestrasse 60 | |
| 8500 Frauenfeld | |
| Switzerland | |
| Phone: | +41 52 724 08 14 |
| Internet: | www.zurrosegroup.com |
| ISIN: | CH0042615283 |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1148445 |
| End of Announcement | EQS Group News Service |
Editor Details
-
Company:
- EQS Newsfeed
- Website:
